

✓ NEW INDICATION ✓ NOW APPROVED



TRYNGOLZA: Expand What's Possible With Triglyceride Reduction in Severe Hypertriglyceridemia (sHTG; TGs $\geq$ 500 mg/dL)¹

Join us for a presentation on TRYNGOLZA, the first and only FDA-approved therapy to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG, as adjunct to diet¹.

See event details below and register to attend.

Featuring:



Who

John C. Isaac
MD

Clinical Instructor Interventional
Fellows Baylor College of Medicine
Program; Chief Financial Officer
Willowbrook Cardiovascular
Associates, P.A.



When

Tuesday, August 11, 2026
6:30 PM CST



Where

Dakotas Steaks – Seafood – Chops
4803 Old Bullard Road #1 Tyler, TX 75703

Register: portal.pharmethod.com/ionis/register or scan the QR code

Program ID: 30815



Questions? Contact your Clinical Account Specialist:

Toby Deupree | 430-235-8835 | tdeupree@ionis.com

Ionis complies with the Open Payments Act and the PhRMA Code on Interactions With Health Care Professionals. Therefore, spouses, partners, or guests may not attend any meeting or social function. This meeting may be photographed and/or videotaped for educational purposes post event. This event is not certified for CME/CE credit.

CE=continuing education; CME=continuing medical education; PhRMA=Pharmaceutical Research and Manufacturers of America.

INDICATION

TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (TG $\geq$ 500 mg/dL, sHTG).

SELECT IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.

Please see Important Safety Information throughout and accompanying full Prescribing Information for TRYNGOLZA, also available at tryngolzahcp.com.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

Liver Enzyme Abnormalities

TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation or an increase in dosage and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption and/or dose reduction. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.

ADVERSE REACTIONS

Most common adverse reactions in patients with sHTG (incidence $\geq 2\%$ higher than placebo) were injection site reactions and liver enzyme increases.

Please see Important Safety Information throughout and accompanying full Prescribing Information for TRYNGOLZA, also available at tryngolzahcp.com.

1. TRYNGOLZA. Prescribing information. Ionis Pharmaceuticals.